



Immune Mediated Inflammatory Diseases: From an Update on Molecular and Cellular Mechanisms to Biomarkers for Personalized Medicine

Guest Editor:

Dr. Frédérique Ponchel
NIHR Leeds Musculoskeletal
Biomedical Research Unit,
University of Leeds, Leeds, UK

Deadline for manuscript
submissions:
closed (31 August 2021)

Message from the Guest Editor

Dear Colleagues,

IMIDs are common conditions which cause pain, distress and loss of function, characterised by a burden of inflammatory leading to organ damage and increased morbidity and/or mortality. Inflammation may result from or be caused by an inadequate immune response for which an autoantigen has been identified in some conditions. An underlying manifestation of this shared immune dysregulation in clinically unrelated conditions is the inappropriate activation of inflammatory cytokines, notably, IL6 or TNF-alpha.

The Special Issue is related to new insight into the mechanism of in IMIDs from molecular and cellular events leading to the establishment of chronicity in these diseases, from epigenetics, gene expression, phenotyping or functional work, cytokine/chemokines networkingetc. Research into biomarker for diagnostic, prognostic and prediction of response to treatment / relapse, are also invited from any stage of development from discovery to validation/replication studies. Both original research and comprehensive review are welcomed.

Prof. Frédérique Ponchel
Guest Editor



mdpi.com/si/34516

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)